Author:
Qi Guangzhao,Zhang Jingmin,Han Chao,Zhou Yubing,Li Duolu,Ma Pengfei
Abstract
AbstractInter-individual differences of drug responses could be attributed to genetic variants of pharmacogenes such as cytochrome P450 (CYP), phase 2 enzymes, and transporters. In contrast to extensive studies on the genetic polymorphisms of CYP gene, genetic mutation spectrum of other pharmacogenes was under-representative in the pharmacogenetics investigations. Here we studied the genetic variations of 125 pharmacogenes including drug transporters, non-CYP phase 1 enzymes, phase 2 enzymes, nuclear receptors and others in Chinese from the Chinese Millionome Database (CMDB), of which 38,188 variants were identified. Computational analyses of the 2554 exonic variants found 617 deleterious missense variants, 91.1% of which were rare, and of the 54 loss-of-function (splice acceptor, splice donor, start lost, and stop gained) variants, 53 (98.1%) were rare. These results suggested an enrichment of rare variants in functional ones for pharmacogenes. Certain common functional variants including NUDT15 13:48611934 G/A (rs186364861), UGT1A1 2:234676872 C/T (rs34946978), and ALDH2 12:112241766 G/A (rs671) were population-specific for CMDB Chinese because they were absent (with a zero of variant allele frequency) or very rare in other gnomAD populations. These findings might be useful for the further pharmacogenomics research and clinical application in Chinese.
Funder
Young Investigators Foundation of The First Affiliated Hospital of Zhengzhou University
Joint Projects of Medical Science and Technology Problem-Tackling Plan of Henan Province
Natural Science Foundation of Henan Province
Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Reference25 articles.
1. Zanger, U. M. & Schwab, M. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther. 138, 103–141 (2013).
2. Anderson, H. D., Crooks, K. R., Kao, D. P. & Aquilante, C. L. The landscape of pharmacogenetic testing in a US managed care population. Genet. Med. 22, 1247–1253 (2020).
3. Youssef, E., Kirkdale, C. L., Wright, D. J., Guchelaar, H. J. & Thornley, T. Estimating the potential impact of implementing pre-emptive pharmacogenetic testing in primary care across the UK. Br. J. Clin. Pharmacol. 2, 2 (2021).
4. Liu, N. et al. Association of ABCC2 polymorphism and gender with high-density lipoprotein cholesterol response to simvastatin. Pharmacogenomics 19, 1125–1132 (2018).
5. Du, Z. et al. Influence of UGT2B7 and UGT1A6 polymorphisms on plasma concentration to dose ratio of valproic acid in Chinese epileptic children. Xenobiotica 2, 1–6 (2021).
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献